uniQure N.V.

DB:UQ1 Stock Report

Market Cap: €270.6m

uniQure Valuation

Is UQ1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UQ1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UQ1 (€5.38) is trading below our estimate of fair value (€11.75)

Significantly Below Fair Value: UQ1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UQ1?

Key metric: As UQ1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for UQ1. This is calculated by dividing UQ1's market cap by their current revenue.
What is UQ1's PS Ratio?
PS Ratio9.9x
SalesUS$28.59m
Market CapUS$281.74m

Price to Sales Ratio vs Peers

How does UQ1's PS Ratio compare to its peers?

The above table shows the PS ratio for UQ1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.6x
HPHA Heidelberg Pharma
12x16.6%€103.9m
FYB Formycon
14x33.4%€827.2m
BIO3 Biotest
1.5x3.6%€1.4b
MDG1 Medigene
3x16.1%€22.6m
UQ1 uniQure
9.9x35.8%€281.7m

Price-To-Sales vs Peers: UQ1 is expensive based on its Price-To-Sales Ratio (9.9x) compared to the peer average (7.6x).

Price to Sales Ratio vs Industry

How does UQ1's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
UQ1 9.9xIndustry Avg. 8.1xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: UQ1 is expensive based on its Price-To-Sales Ratio (9.9x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is UQ1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UQ1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.9x
Fair PS Ratio0.1x

Price-To-Sales vs Fair Ratio: UQ1 is expensive based on its Price-To-Sales Ratio (9.9x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UQ1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.38
€17.58
+226.7%
40.6%€26.09€6.41n/a11
Nov ’25€5.06
€17.79
+251.2%
38.8%€25.96€6.49n/a11
Oct ’25€4.23
€17.73
+319.2%
40.8%€25.96€6.49n/a10
Sep ’25€5.44
€17.77
+226.9%
40.6%€25.96€6.49n/a10
Aug ’25€6.92
€17.50
+152.9%
39.7%€25.96€6.49n/a10
Jul ’25€4.02
€17.06
+324.7%
43.6%€25.98€5.57n/a10
Jun ’25€4.11
€17.07
+315.2%
43.5%€25.98€5.57n/a10
May ’25€3.90
€18.97
+386.0%
37.6%€27.69€6.58n/a11
Apr ’25€4.77
€20.30
+325.5%
42.3%€35.10€6.47n/a11
Mar ’25€5.14
€20.89
+306.4%
39.2%€34.65€6.47n/a12
Feb ’25€4.95
€27.84
+462.4%
47.7%€58.83€9.16n/a12
Jan ’25€5.98
€28.19
+371.5%
47.1%€58.83€9.16n/a12
Dec ’24€6.01
€30.23
+403.0%
40.9%€58.83€13.10n/a11
Nov ’24€5.22
€32.57
+524.0%
34.8%€51.07€13.30€5.0612
Oct ’24€6.24
€33.34
+434.2%
32.6%€51.07€13.08€4.2312
Sep ’24€8.30
€35.00
+321.7%
31.8%€51.07€12.77€5.4414
Aug ’24€9.71
€39.86
+310.5%
38.8%€82.19€12.77€6.9214
Jul ’24€10.02
€42.60
+325.1%
36.2%€82.19€12.79€4.0214
Jun ’24€17.84
€46.56
+161.0%
28.0%€82.86€21.86€4.1114
May ’24€17.32
€50.23
+190.0%
27.6%€85.09€21.86€3.9014
Apr ’24€17.92
€49.48
+176.1%
27.8%€85.09€22.65€4.7715
Mar ’24€19.95
€49.57
+148.6%
27.5%€84.42€22.65€5.1415
Feb ’24€19.22
€49.07
+155.4%
26.8%€84.42€22.10€4.9516
Jan ’24€20.94
€50.15
+139.5%
26.1%€84.42€22.63€5.9816
Dec ’23€24.76
€50.19
+102.7%
26.6%€85.74€23.27€6.0116
Nov ’23€18.92
€50.11
+164.9%
26.6%€87.99€24.68€5.2216

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$707.40

7D

-0.9%

1Y

-3.6%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

1.3%

1Y

89.7%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

3.6%

1Y

22.9%